Storia in 2 fonti

Exclusive: Pathos AI signs two deals, plans to raise Series E at $3B valuation

Pathos AI is raising up to $300M at a ~$3B valuation and inks deals for Alphamab's TROP2/HER3 ADC ($125M upfront) and AstraZeneca's oral ER degrader.

Raccontata da

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo13 h fa

Pathos AI is raising up to $300M at a ~$3B valuation and inks deals for Alphamab's TROP2/HER3 ADC ($125M upfront) and AstraZeneca's oral ER degrader.

Pathos AI Enters Global Licensing Agreement with Alphamab Oncology on JSKN016, a First-in-Class TROP2/HER3 Bispecific ADC